Sino Expands Global Partnerships
Sino Biopharm Secures Major AstraZeneca Licensing Deal, Expands GSK Partnership, Boosting Shares
Key Points
The AstraZeneca deal is being executed through Sino's subsidiary Chia Tai Tianqing Pharmaceutical Group and grants AstraZeneca exclusive global rights to certain future development programs beyond the TQC3721 asset, expanding beyond the single inhaled PDE3/4 inhibitor.
In phase 2 data, TQC3721 showed a peak FEV1 improvement of up to 147 mL at Week 4, a stronger signal than Verona's Ohtuvayre in its comparable phase 2 results, highlighting potential best-in-class potential in the PDE3/4 COPD space.
In May, Sino expanded its collaboration with GSK by entering a strategic agreement to support the launch of hepatitis B therapy bepirovirsen in China, signaling a broader China-focused expansion beyond Trelegy Ellipta and Anoro Ellipta.
The AstraZeneca deal underscores Sino Biopharmaceutical’s use of its pipeline through cross-border licensing, with the first major collaboration via its Chia Tai Tianqing unit and a second major tie-up with GSK demonstrating a broader strategy to monetize assets through multinational partnerships.
Stock market reaction reflected investor enthusiasm, with Sino Biopharm shares rising as much as about 7% in Hong Kong on the news of the AstraZeneca deal and GSK collaboration.
Sino Biopharmaceutical has signed a licensing deal with AstraZeneca worth up to $2.1 billion, handing AstraZeneca exclusive rights outside China to its experimental COPD drug TQC3721. The deal includes a $200 million upfront payment and up to $1.9 billion in potential milestone payments, plus tiered double-digit royalties on net sales, according to Investing.com.
On the same day, Sino expanded its existing partnership with GSK to commercialize two established respiratory medicines in mainland China. Sino shares surged as much as 7% in Hong Kong on the news, Investing.com reported.
TQC3721 Targets a Crowded but Lucrative COPD Market
TQC3721 is an inhaled PDE3/4 inhibitor — a type of drug that relaxes the airways and reduces inflammation in the lungs. It is designed to treat chronic obstructive pulmonary disease, or COPD, a condition that affects hundreds of millions of people worldwide. Fierce Biotech described the drug as a direct challenger to Merck's recently approved COPD drug Ohtuvayre.
Phase 2 data showed TQC3721 improved a key lung-function measure — called FEV1 — by up to 147 mL at Week 4. That is a stronger result than Ohtuvayre posted in its comparable phase 2 study, Fierce Biotech reported, suggesting TQC3721 could become a best-in-class option. A nebulized form of the drug is already in phase 3 trials in China, while a dry powder inhaler version is in phase 2.
AstraZeneca Deal Runs Through Sino's Key Drug Unit
The AstraZeneca agreement is being executed through Sino's subsidiary Chia Tai Tianqing Pharmaceutical Group. It is the first major cross-border licensing deal for that unit. The deal gives AstraZeneca exclusive rights not just to TQC3721, but also to certain future development programs from the same subsidiary, according to Endpoints News.
That broader scope makes this more than a single-asset deal. It sets up a long-term pipeline relationship between the two companies. For Sino, it converts late-stage research into immediate cash and future revenue, without giving up its China business.
GSK Partnership Grows to Include Three Products in China
Sino's expanded deal with GSK adds commercialization rights in mainland China for two respiratory medicines: Trelegy Ellipta and Anoro Ellipta. Sino will handle importation, distribution, hospital access, and promotion for both products, Investing.com reported.
The GSK relationship goes even further. In May, Sino signed a separate agreement with GSK to support the launch of bepirovirsen, a hepatitis B therapy, in China. That deal signals Sino is not limiting its GSK tie-up to respiratory drugs — it is building a broader commercial platform across disease areas.
Sino Builds a Pattern of Big Multinational Deals
The AstraZeneca and GSK deals are part of a clear strategy. Sino has been signing partnerships with global drugmakers to turn its pipeline into cash. Earlier deals with Sanofi and others showed the same playbook: license assets out of China for upfront payments and royalties, while keeping China rights at home, according to Morningstar.
The approach is working for investors. Sino shares have climbed as the deals stack up. The 7% jump on this latest announcement shows the market sees real value in Sino's ability to attract top-tier global partners. With a pipeline of late-stage assets still in hand, more deals could follow.
Sentiment
Mostly PositivePublishers
13
Articles
72
Reach
85
